Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10
Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez Lynch, a health-policy professor at the University of Pennsylvania, commented on the FDA’s cautious stance, saying, “Hold on, we’re not actually sure this product should be allowed on the market,” highlighting the agency’s readiness to slow fast-tracked reviews.
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push
Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next
Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning.
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens
Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound.
Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention
NVIDIA Corporation shares barely moved Tuesday following a report that China is restricting approvals for buying the company’s H200 AI chips. The stock last dipped 0.04% to $184.87 shortly after the close, after bouncing between $183.45 and $188.08.
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms
Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration's request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy.
Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus
Nvidia shares held steady in early New York trading Tuesday after the company announced it won’t require upfront payments for its H200 AI chips. The stock ticked up just 0.03% to $184.94.
Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus
Nvidia shares showed little movement in premarket trading Tuesday following the company’s announcement that customers won’t need to pay upfront for its H200 chip, a data-center GPU designed for AI model training and deployment. The stock inched up roughly 0.03% to $184.94.
Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal
Eli Lilly stock rose about 1.6% in after-hours trading on Monday, last at $1,081, after a top research executive said the drugmaker expects to have enough supply to launch its experimental weight-loss pill orforglipron in “many, many countries” as it nears a U.S. regulatory decision.
Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands
Nvidia shares held steady in after-hours trading Monday following the announcement that the chipmaker and Eli Lilly plan to launch a joint AI research lab focused on accelerating drug discovery.
Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings
Nvidia shares climbed roughly 0.8% Monday following news the chipmaker and Eli Lilly plan to pour up to $1 billion into an AI lab designed to accelerate drug discovery over the next five years. Nvidia closed at $186.37, while Lilly edged up about 0.2% to $1,066.14.
Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom
Nvidia, the world’s most valuable listed company, and Eli Lilly said on Monday they will spend $1 billion over five years on a joint research lab in the San Francisco Bay Area, betting Nvidia’s next Vera Rubin AI chips can speed drug discovery. Nvidia shares were down 0.2% at $184.42 by 10:30 a.m. ET.
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight
Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery.
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next
Eli Lilly and Company shares dropped 1.99% on Friday, closing at $1,063.56. The stock heads into Monday’s session under pressure after a volatile week for major pharmaceutical firms.
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds
U.S. healthcare stocks ended the week weaker, with the Health Care Select Sector SPDR Fund slipping 0.5% to $157.31 on Friday. This ETF, often seen as a benchmark for major U.S. healthcare companies, has shown volatility as investors brace for a packed schedule of sector developments.
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY
Eli Lilly & Co shares fell 2% on Friday to $1,063.56, underperforming a stronger broader market and extending a two-day slide. The stock is now 6.21% below its 52-week high of $1,133.95 set on Thursday, while trading volume ran below its recent average.
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens
Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority platform partner for TuneLab workflows,” said Pat Lorton, Schrödinger’s software chief.